DSM invests in IntegraGen
This article was originally published in The Tan Sheet
Executive Summary
The Netherlands-based firm has invested $2.6 mil. (€1 = $1.28) in IntegraGen, a French biotechnology company specializing in the development and delivery of genetic tests for rapid diagnosis and better treatment of complex diseases, DSM announces Nov. 7. "IntraGen's proprietary GenomeHIP technology platform identifies disease genes by allowing the rapid comparison of genomes of family members affected with the same disease," the release states. IntegraGen also "recognizes the potential of its know-how in personalized nutrition," which has led to a collaboration program in the area of weight management, the release says. Recently, DSM collaborated with the European Genetic Alliances Network and the International Genetic Alliance to promote health management and "the contribution of functional foods ingredients" to patient and consumer organizations (1"The Tan Sheet," Oct. 30, 2006, In Brief)...